Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 2/2014

01.06.2014 | Pros and Cons in Endocrine Practice

Cabergoline treatment in acromegaly: cons

verfasst von: Leandro Kasuki, Leonardo Vieira Neto, Mônica R. Gadelha

Erschienen in: Endocrine | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Many options are available for the treatment of acromegaly, including surgery, radiotherapy, and medical treatment. Cabergoline (CAB), a dopamine agonist with high affinity for dopamine receptor type 2, has been used both in monotherapy and in conjunction with somatostatin analogs (SSAs). Although it is administered orally and has a relatively lower-cost in comparison with SSAs, few studies have demonstrated its usefulness, there is a lack of randomized-controlled trials and other drugs (SSAs and pegvisomant) with more data in the literature are available; these issues are the main drawbacks of adopting CAB for the treatment of acromegaly.
Literatur
1.
S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009)PubMedCrossRef
2.
L. Vieira Neto, J. Abucham, L.A. Araujo, C.L. Boguszewski, M.D. Bronstein, M. Czepielewski, R.S. Jallad, N.R. Musolino, L.A. Naves, A. Ribeiro-Oliveira Junior, L. Vilar, S. Faria Mdos, M.R. Gadelha, Recommendations of neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil. Arq. Bras. Endocrinol. Metab. 55(2), 91–105 (2011)CrossRef
3.
R. Abs, J. Verhelst, D. Maiter, K. Van Acker, F. Nobels, J.L. Coolens, C. Mahler, A. Beckers, Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. 83(2), 374–378 (1998)PubMedCrossRef
4.
R. Cozzi, R. Attanasio, M. Barausse, D. Dallabonzana, P. Orlandi, N. Da Re, V. Branca, G. Oppizzi, D. Gelli, Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur. J. Endocrinol. 139(5), 516–521 (1998)PubMedCrossRef
5.
P.U. Freda, C.M. Reyes, A.T. Nuruzzaman, R.E. Sundeen, A.G. Khandji, K.D. Post, Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary 7(1), 21–30 (2004)PubMedCrossRef
6.
B. Gatta, D.H. Hau, B. Catargi, P. Roger, A. Tabarin, Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin. Endocrinol. (Oxf) 63(4), 477–478 (2005)CrossRef
7.
P. Nomikos, M. Buchfelder, R. Fahlbusch, The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur. J. Endocrinol. 152(3), 379–387 (2005)PubMedCrossRef
8.
P.U. Freda, L. Katznelson, A.J. van der Lely, C.M. Reyes, S. Zhao, D. Rabinowitz, Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 90(8), 4465–4473 (2005)PubMedCrossRef
9.
A. Mestron, S.M. Webb, R. Astorga, P. Benito, M. Catala, S. Gaztambide, J.M. Gomez, I. Halperin, T. Lucas-Morante, B. Moreno, G. Obiols, P. de Pablos, C. Paramo, A. Pico, E. Torres, C. Varela, J.A. Vazquez, J. Zamora, M. Albareda, M. Gilabert, Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur. J. Endocrinol. 151(4), 439–446 (2004)PubMedCrossRef
10.
M. Mercado, F. Borges, H. Bouterfa, T.C. Chang, A. Chervin, A.J. Farrall, A. Patocs, S. Petersenn, J. Podoba, M. Safari, J. Wardlaw, S.B.S. Group, A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin. Endocrinol. (Oxf) 66(6), 859–868 (2007)CrossRef
11.
S. Melmed, D. Cook, J. Schopohl, M.I. Goth, K.S. Lam, J. Marek, Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 13(1), 18–28 (2010)PubMedCentralPubMedCrossRef
12.
W. Drake, C. Stiles, T. Howlett, A. Toogood, J. Bevan, R. Steeds, A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J. Clin. Endocrinol. Metab. 99(1), 90–96 (2013)
13.
A. Giustina, I. Karamouzis, I. Patelli, G. Mazziotti, Octreotide for acromegaly treatment: a reappraisal. Expert Opin. Pharmacother. 14(17), 2433–2447 (2013)PubMedCrossRef
14.
A. Colao, P. Cappabianca, P. Caron, E. De Menis, A.J. Farrall, M.R. Gadelha, A. Hmissi, A. Rees, M. Reincke, M. Safari, G. T’Sjoen, H. Bouterfa, R.C. Cuneo, Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin. Endocrinol. (Oxf) 70(5), 757–768 (2009)CrossRef
15.
L. Sandret, P. Maison, P. Chanson, Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96(5), 1327–1335 (2011)PubMedCrossRef
16.
A. Colao, D. Ferone, P. Marzullo, A. Di Sarno, G. Cerbone, F. Sarnacchiaro, S. Cirillo, B. Merola, G. Lombardi, Effect of different dopaminergic agents in the treatment of acromegaly. J. Clin. Endocrinol. Metab. 82(2), 518–523 (1997)PubMedCrossRef
17.
V.J. Moyes, K.A. Metcalfe, W.M. Drake, Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur. J. Endocrinol. 159(5), 541–545 (2008)PubMedCrossRef
18.
T.A. Howlett, D. Willis, G. Walker, J.A. Wass, P.J. Trainer, Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin. Endocrinol. (Oxf) 79(5), 689–699 (2013)
19.
A. Giustina, G. Mazziotti, V. Torri, M. Spinello, I. Floriani, S. Melmed, Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 7(5), e36411 (2012)PubMedCentralPubMedCrossRef
20.
G. Mazziotti, A. Giustina, Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13(1), 60–67 (2010)PubMedCrossRef
21.
M. Sherlock, E. Fernandez-Rodriguez, A.A. Alonso, R.C. Reulen, J. Ayuk, R.N. Clayton, G. Holder, M.C. Sheppard, A. Bates, P.M. Stewart, Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J. Clin. Endocrinol. Metab. 94(4), 1255–1263 (2009)PubMedCrossRef
22.
R. Cozzi, R. Attanasio, S. Lodrini, G. Lasio, Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol. (Oxf) 61(2), 209–215 (2004)CrossRef
23.
R.S. Jallad, M.D. Bronstein, Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 90(1), 82–92 (2009)PubMedCrossRef
24.
P. Marzullo, D. Ferone, C. Di Somma, R. Pivonello, M. Filippella, G. Lombardi, A. Colao, Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1(2), 115–120 (1999)PubMedCrossRef
25.
D. Selvarajah, J. Webster, R. Ross, J. Newell-Price, Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur. J. Endocrinol. 152(4), 569–574 (2005)PubMedCrossRef
26.
L. Vilar, M.F. Azevedo, L.A. Naves, L.A. Casulari, J.L. Albuquerque, R.M. Montenegro, R.M. Montenegro Jr, P. Figueiredo, G.C. Nascimento, M.S. Faria, Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary 14(2), 148–156 (2011)PubMedCrossRef
27.
P. Mattar, M.R. Alves Martins, J. Abucham, Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Neuroendocrinology 92(2), 120–127 (2010)PubMedCrossRef
28.
K. Suda, N. Inoshita, G. Iguchi, H. Fukuoka, M. Takahashi, H. Nishizawa, M. Yamamoto, S. Yamada, Y. Takahashi, Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocr. J. 60(4), 507–515 (2013)PubMed
29.
S.J. Neggers, A.J. van der Lely, Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Hormon IGF Res 21(3), 129–133 (2011)CrossRef
30.
S.J. Neggers, W.W. de Herder, J.A. Janssen, R.A. Feelders, A.J. van der Lely, Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur. J. Endocrinol. 160(4), 529–533 (2009)PubMedCrossRef
31.
S.J. Neggers, M.O. van Aken, J.A. Janssen, R.A. Feelders, W.W. de Herder, A.J. van der Lely, Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab. 92(12), 4598–4601 (2007)PubMedCrossRef
32.
E. Resmini, P. Dadati, J.L. Ravetti, G. Zona, R. Spaziante, A. Saveanu, P. Jaquet, M.D. Culler, F. Bianchi, A. Rebora, F. Minuto, D. Ferone, Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J. Clin. Endocrinol. Metab. 92(5), 1592–1599 (2007)PubMedCrossRef
33.
M. Gola, S. Bonadonna, G. Mazziotti, G. Amato, A. Giustina, Resistance to somatostatin analogs in acromegaly: an evolving concept? J. Endocrinol. Invest. 29(1), 86–93 (2006)PubMed
34.
C.E. Higham, A.B. Atkinson, S. Aylwin, M. Bidlingmaier, W.M. Drake, A. Lewis, N.M. Martin, V. Moyes, J. Newell-Price, P.J. Trainer, Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J. Clin. Endocrinol. Metab. 97(4), 1187–1193 (2012)PubMedCrossRef
35.
I. Bernabeu, C. Alvarez-Escola, A.E. Paniagua, T. Lucas, I. Pavon, J.M. Cabezas-Agricola, F.F. Casanueva, M. Marazuela, Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 16(1), 101–108 (2013)PubMedCrossRef
36.
J. Martinkova, L. Trejbalova, M. Sasikova, J. Benetin, P. Valkovic, Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin. Neuropharmacol. 34(5), 179–181 (2011)PubMedCrossRef
37.
L. Bancos, M.R. Nannenga, J.M. Bostwick, M.H. Silber, D. Erickson, T.B. Nippoldt, Impulse control disorders in patients with dopamine agonist-treated prolactinomas and non-functioning pituitary adenomas: a case-control study. Clin. Endocrinol. (Oxf) (2013). doi:10.​1111/​cen.​12375
38.
R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, G. Pezzoli, Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. New Engl. J. Med. 356(1), 39–46 (2007)PubMedCrossRef
39.
R. Schade, F. Andersohn, S. Suissa, W. Haverkamp, E. Garbe, Dopamine agonists and the risk of cardiac-valve regurgitation. New Engl. J. Med. 356(1), 29–38 (2007)PubMedCrossRef
40.
L. Maione, C. Garcia, A. Bouchachi, N. Kallel, P. Maison, S. Salenave, J. Young, P. Assayag, P. Chanson, No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J. Clin. Endocrinol. Metab. 97(9), E1714–E1719 (2012)PubMedCrossRef
41.
R. De Vecchis, C. Esposito, C. Ariano, Cabergoline use and risk of fibrosis and insufficiency of cardiac valves: meta-analysis of observational studies. Herz 38(8), 868–880 (2013)
42.
R.S. Auriemma, R. Pivonello, Y. Perone, L.F. Grasso, L. Ferreri, C. Simeoli, D. Iacuaniello, M. Gasperi, A. Colao, Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur. J. Endocrinol. 169(3), 359–366 (2013)PubMedCrossRef
43.
A. Colao, M. Galderisi, A. Di Sarno, M. Pardo, M. Gaccione, M. D’Andrea, E. Guerra, R. Pivonello, G. Lerro, G. Lombardi, Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J. Clin. Endocrinol. Metab. 93(10), 3777–3784 (2008)PubMedCrossRef
44.
A. Elenkova, R. Shabani, K. Kalinov, S. Zacharieva, Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur. J. Endocrinol. 167(1), 17–25 (2012)PubMedCrossRef
45.
A.M. Pereira, S.W. van Thiel, J.R. Lindner, F. Roelfsema, E.E. van der Wall, H. Morreau, J.W. Smit, J.A. Romijn, J.J. Bax, Increased prevalence of regurgitant valvular heart disease in acromegaly. J. Clin. Endocrinol. Metab. 89(1), 71–75 (2004)PubMedCrossRef
46.
A.A. van der Klaauw, J.J. Bax, F. Roelfsema, G.B. Bleeker, E.R. Holman, E.P. Corssmit, E.E. van der Wall, J.W. Smit, J.A. Romijn, A.M. Pereira, Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Hormon. IGF Res. 16(2), 101–107 (2006)CrossRef
47.
A. Colao, L. Spinelli, P. Marzullo, R. Pivonello, M. Petretta, C. Di Somma, G. Vitale, D. Bonaduce, G. Lombardi, High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J. Clin. Endocrinol. Metab. 88(7), 3196–3201 (2003)PubMedCrossRef
48.
C. Izgi, H. Feray, C. Cevik, Y. Saltan, D. Mansuroglu, K. Nugent, Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly. J. Heart Valve Dis. 19(6), 797–800 (2010)PubMed
Metadaten
Titel
Cabergoline treatment in acromegaly: cons
verfasst von
Leandro Kasuki
Leonardo Vieira Neto
Mônica R. Gadelha
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0183-4

Weitere Artikel der Ausgabe 2/2014

Endocrine 2/2014 Zur Ausgabe

Endocrine Methods and Techniques

Establishment of robust controls for the normalization of miRNA expression in neuroendocrine tumors of the ileum and pancreas

Review

Molecular basis of pharmacological therapy in Cushing’s disease

Original Article

Lack of sensorial innervation in the newborn female rats affects the activity of hypothalamic monoaminergic system and steroid hormone secretion during puberty

Original Article

Clinical implication of elevated CA 19-9 level and the relationship with glucose control state in patients with type 2 diabetes

Original Article

Hyperhomocysteinemia is an independent predictor of sub-clinical carotid vascular damage in subjects with grade-1 hypertension

Pros and Cons in Endocrine Practice

Cabergoline treatment in acromegaly: pros

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise